Deep Track Capital, LP — Quarter-over-Quarter 13F Allocation Shifts Q1 2026
In Q1 2026, Deep Track Capital, LP initiated 16 new positions, increased allocation to 10 existing positions, trimmed 10 positions, and exited 7 positions entirely. The fund's 13F equity book grew from $4.38B to $4.85B (+10.6% QoQ) . All deltas are sourced from sequential SEC Form 13F-HR filings; share-count changes reflect explicit trading activity, while weight changes can also include price movement. This page lists every position change reported — the portfolio overview shows a summary of the top shifts.
Net Portfolio Value Change
- $4.38BPrior quarter
- $4.85BCurrent quarter
- + $0.46BNet delta
- +10.6%% change
New Position Initiations Q1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Allocation Weight | History |
|---|---|---|---|
| ALUMIS INC. | ALMS | 3.08% | History → |
| NUVALENT INC | NUVL | 2.91% | Holders → |
| GENMAB A/S | GMAB | 2.03% | Holders → |
| DEFINIUM THERAPEUTICS INC | DFTX | 1.17% | Holders → |
| ATAIBECKLEY INC | ATAI | 0.88% | Holders → |
| CORVUS PHARMACEUTICALS INC | CRVS | 0.75% | Holders → |
| ACLARIS THERAPEUTICS INC | ACRS | 0.72% | Holders → |
| VERADERMICS INC | MANE | 0.65% | Holders → |
| SOLID BIOSCIENCES INC | SLDB | 0.53% | Holders → |
| APOGEE THERAPEUTICS INC | APGE | 0.49% | Holders → |
| KURA ONCOLOGY INC | KURA | 0.44% | Holders → |
| CENTURY THERAPEUTICS INC | IPSC | 0.44% | Holders → |
| BEAM THERAPEUTICS INC | BEAM | 0.40% | Holders → |
| PERSONALIS INC | PSNL | 0.39% | Holders → |
| PROMIS NEUROSCIENCES INC | PMN | 0.22% | Holders → |
| LARIMAR THERAPEUTICS INC | LRMR | 0.14% | Holders → |
Largest Allocation Increases Q1 2026
Largest portfolio-weight increases in existing positions. Share-count delta is shown separately so price-only re-weighting can be distinguished from active adds.
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| JANUX THERAPEUTICS INC | JANX | +0.31% | +1225.26% | Holders → |
| INVENTIVA SA | IVA | +0.09% | +149.48% | Holders → |
| OCULAR THERAPEUTIX INC | OCUL | +1.21% | +143.93% | History → |
| COGENT BIOSCIENCES INC | COGT | +0.43% | +120.70% | Holders → |
| ALKERMES PLC | ALKS | +1.34% | +79.52% | Holders → |
| GRAIL, INC. | GRAL | +-0.16% | +68.44% | Holders → |
| COMPASS PATHWAYS PLC | CMPS | +0.23% | +65.82% | Holders → |
| CENTESSA PHARMACEUTICALS PLC | CNTA | +1.45% | +57.90% | Holders → |
| BICARA THERAPEUTICS INC | BCAX | +0.66% | +55.41% | Holders → |
| VERA THERAPEUTICS INC | VERA | +0.15% | +45.55% | History → |
Largest Allocation Reductions Q1 2026
Largest portfolio-weight decreases in existing positions (positions kept open at a lower allocation).
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| CYTOKINETICS INC | CYTK | -2.97% | -58.82% | Holders → |
| BIOMARIN PHARMACEUTICALS | BMRN | -1.78% | -50.00% | Holders → |
| VIRIDIAN THERAPEUTICS, INC. | VRDN | -1.23% | -44.79% | Holders → |
| APELLIS PHARMACEUTICALS INC | APLS | -0.68% | -41.52% | History → |
| CELLDEX THERAPEUTICS INC | CLDX | -0.34% | -32.45% | Holders → |
| CYBIN INC | HELP | -0.22% | -29.18% | Holders → |
| DYNE THERAPEUTICS INC | DYN | -0.43% | -24.53% | Holders → |
| MAZE THERAPEUTICS INC | MAZE | -1.87% | -18.11% | Holders → |
| MBX BIOSCIENCES INC | MBX | -0.64% | -15.15% | Holders → |
| NURIX THERAPEUTICS INC | NRIX | -1.02% | -9.82% | Holders → |
Exited Positions Q1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORP | SYN_268158201 | 5.52% |
| MIND MEDICINE MINDMED INC | SYN_60255C885 | 0.51% |
| ATAI BECKLEY NV | SYN_N0731H103 | 0.44% |
| XENON PHARMACEUTICALS INC | XENE | 0.37% |
| MONOPAR THERAPEUTICS INC | MNPR | 0.14% |
| RAPT THERAPEUTICS INC | SYN_75382E208 | 0.09% |
| ADLAI NORTYE LTD | ANL | 0.00% |
Methodology & FAQ
How Deep Track Capital, LP Quarterly Changes Are Computed
Each row above is computed by joining the most recent 13F-HR filing for Deep Track Capital, LP against the immediately preceding quarterly filing for the same fund. Portfolio weights are normalized to exclude listed options for comparability. A complete description of the methodology — including how confidential treatment filings are handled and why share count rather than weight is the cleaner trading signal — is documented in the Methodology.
Which positions did Deep Track Capital, LP initiate in Q1 2026?
Deep Track Capital, LP established 16 new positions in Q1 2026: ALUMIS INC. (ALMS, 3.08%), NUVALENT INC (NUVL, 2.91%), GENMAB A/S (GMAB, 2.03%), DEFINIUM THERAPEUTICS INC (DFTX, 1.17%), ATAIBECKLEY INC (ATAI, 0.88%), CORVUS PHARMACEUTICALS INC (CRVS, 0.75%), ACLARIS THERAPEUTICS INC (ACRS, 0.72%), VERADERMICS INC (MANE, 0.65%), SOLID BIOSCIENCES INC (SLDB, 0.53%), APOGEE THERAPEUTICS INC (APGE, 0.49%), KURA ONCOLOGY INC (KURA, 0.44%), CENTURY THERAPEUTICS INC (IPSC, 0.44%), BEAM THERAPEUTICS INC (BEAM, 0.40%), PERSONALIS INC (PSNL, 0.39%), PROMIS NEUROSCIENCES INC (PMN, 0.22%), LARIMAR THERAPEUTICS INC (LRMR, 0.14%).
Which existing positions saw the largest allocation increases for Deep Track Capital, LP in Q1 2026?
The largest portfolio-weight increases in existing positions were: JANUX THERAPEUTICS INC (JANX, +0.31% weight, +1225.26% shares), INVENTIVA SA (IVA, +0.09% weight, +149.48% shares), OCULAR THERAPEUTIX INC (OCUL, +1.21% weight, +143.93% shares), COGENT BIOSCIENCES INC (COGT, +0.43% weight, +120.70% shares), ALKERMES PLC (ALKS, +1.34% weight, +79.52% shares), GRAIL, INC. (GRAL, +-0.16% weight, +68.44% shares), COMPASS PATHWAYS PLC (CMPS, +0.23% weight, +65.82% shares), CENTESSA PHARMACEUTICALS PLC (CNTA, +1.45% weight, +57.90% shares), BICARA THERAPEUTICS INC (BCAX, +0.66% weight, +55.41% shares), VERA THERAPEUTICS INC (VERA, +0.15% weight, +45.55% shares).
Which positions did Deep Track Capital, LP fully exit in Q1 2026?
Deep Track Capital, LP fully exited 7 positions in Q1 2026: DYNAVAX TECHNOLOGIES CORP (SYN_268158201, last-reported weight 5.52%), MIND MEDICINE MINDMED INC (SYN_60255C885, last-reported weight 0.51%), ATAI BECKLEY NV (SYN_N0731H103, last-reported weight 0.44%), XENON PHARMACEUTICALS INC (XENE, last-reported weight 0.37%), MONOPAR THERAPEUTICS INC (MNPR, last-reported weight 0.14%), RAPT THERAPEUTICS INC (SYN_75382E208, last-reported weight 0.09%), ADLAI NORTYE LTD (ANL, last-reported weight 0.00%).
Which existing positions saw the largest allocation reductions for Deep Track Capital, LP in Q1 2026?
The largest portfolio-weight reductions in positions kept open were: CYTOKINETICS INC (CYTK, -2.97% weight, -58.82% shares), BIOMARIN PHARMACEUTICALS (BMRN, -1.78% weight, -50.00% shares), VIRIDIAN THERAPEUTICS, INC. (VRDN, -1.23% weight, -44.79% shares), APELLIS PHARMACEUTICALS INC (APLS, -0.68% weight, -41.52% shares), CELLDEX THERAPEUTICS INC (CLDX, -0.34% weight, -32.45% shares), CYBIN INC (HELP, -0.22% weight, -29.18% shares), DYNE THERAPEUTICS INC (DYN, -0.43% weight, -24.53% shares), MAZE THERAPEUTICS INC (MAZE, -1.87% weight, -18.11% shares), MBX BIOSCIENCES INC (MBX, -0.64% weight, -15.15% shares), NURIX THERAPEUTICS INC (NRIX, -1.02% weight, -9.82% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity.